(Q36546281)

14 August 2017

1 reference

title

The adjuvant endocrine treatment revolution: focus on anastrozole (English)

1 reference

14 August 2017

Raimund Jakesz

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

published in

1 reference

14 August 2017

volume

2

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

301-312

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Aromatase inhibitors in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Arimidex: a potent and selective fourth-generation aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Optimizing endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Meta-analysis of vascular and neoplastic events associated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.2.301

21 January 2018

Identifiers

DOI

10.1517/17425255.2.2.301

1 reference

14 August 2017

1 reference